cytomegalovirus pp65-specific cytotoxic t lymphocytes
Cell therapyexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2007 (NCT00509691)
Timeline
2000s
- Jan 1, 2007
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- CytomegalovirusImmunity, passive
Cytomegalovirus immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cytomegalovirus pp65-specific cytotoxic t lymphocytes
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00769613 | Phase 1 | Aug 1, 2008 | National Cancer Institute (NCI), Pennsylvania State University |
| NCT00509691 | Phase 1 | Jun 1, 2007 | Pennsylvania State University, University of Louisville |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pennsylvania State University | Academic/Hospital | 2 | 1 | 1 | 2007 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2008 |
| University of Louisville | Academic/Hospital | 1 | 1 | 1 | 2007 |
3 organizations
Page 1 / 1